Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Development programme

SURMOUNT — tirzepatide in obesity — page 2

The phase 3 weight-management programme for the dual GIP and GLP-1 receptor agonist tirzepatide, including trials in participants with and without type 2 diabetes, a maintenance-withdrawal design and a dedicated obstructive sleep apnoea programme.

Showing 0 records on this page

Records in this programme

26 documents · page 2 of 2

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
SURMOUNT-OSA-1-OLEprogramme recordTirzepatidePhase 3ReportedSingle-arm open-label—2024Very low
SURMOUNT-OSA-2-BODY-COMPprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled—2024Very low

page 2 of 2

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.